
Gastrin analogue against diabetes
Transition Therapeutics Inc. announced that the first patient has been dosed in a Phase 2 clinical study of gastrin analogue, TT-223, in patients with type 2 diabetes. Gastrin based therapies are an emerging class of potential disease-modifying treatments for patients with diabetes.





















